Interaction between Promethazine and Cabozantinib
Major Synergy

ID DDInter1533 and DDInter262
Interaction Cabozantinib can cause prolongation of the QT interval.
Management Caution and close clinical monitoring are recommended if cabozantinib is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
References
Alternative for Promethazine R06A
Desloratadine
Ketotifen
Cyproheptadine
Methdilazine
Phenindamine
Thiethylperazine
Cyclizine
Azelastine
Chlorpheniramine
Clemastine
Diphenhydramine
More
Alternative for Cabozantinib L01X
Abemaciclib
Belinostat
Obinutuzumab
Ixazomib
Regorafenib
Panitumumab
Acalabrutinib
Enasidenib
Trastuzumab emtansine
Vorinostat
Everolimus
More

Potential Metabolism Interactions

Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.